MCID: BLD054
MIFTS: 43

Blood Protein Disease

Categories: Blood diseases

Aliases & Classifications for Blood Protein Disease

MalaCards integrated aliases for Blood Protein Disease:

Name: Blood Protein Disease 12 15 74
Blood Protein Disorders 45 74
Blood Protein Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:620
MeSH 45 D001796

Summaries for Blood Protein Disease

MalaCards based summary : Blood Protein Disease, also known as blood protein disorders, is related to poems syndrome and sickle cell anemia. An important gene associated with Blood Protein Disease is MYOM2 (Myomesin 2), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Selenium Micronutrient Network. The drugs Melphalan and Bortezomib have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 77 Blood proteins, also termed plasma proteins, are proteins present in blood plasma. They serve many... more...

Related Diseases for Blood Protein Disease

Diseases related to Blood Protein Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 poems syndrome 31.4 IL6 MYOM2 VEGFA
2 sickle cell anemia 31.1 BCL11A F2 HBB HBS1L MTHFR
3 monoclonal gammopathy of uncertain significance 29.9 B2M CD38 IL6 MAG MYOM2 NCAM1
4 hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 10.4 BCL11A HBB
5 indolent myeloma 10.4 B2M MYOM2
6 hemoglobinemia 10.4 B2M HBB
7 mononeuritis multiplex 10.4 MAG MYOM2
8 mononeuritis of upper limb and mononeuritis multiplex 10.4 MAG MYOM2
9 alpha-2-plasmin inhibitor deficiency 10.4 F2 SERPINC1
10 immunodeficiency due to a classical component pathway complement deficiency 10.4 C4A C4B
11 intracranial embolism 10.4 F2 SERPINC1
12 median neuropathy 10.4 MYOM2 VEGFA
13 prothrombin deficiency, congenital 10.3 F2 SERPINC1
14 chronic polyneuropathy 10.3 MAG MYOM2
15 juvenile dermatitis herpetiformis 10.3 C4A C4B
16 glomeruloid hemangioma 10.3 MYOM2 VEGFA
17 mesenteric vascular occlusion 10.3 F2 MTHFR
18 hemoglobin e disease 10.3 F2 HBB HBS1L
19 acute endophthalmitis 10.3 C4A VEGFA
20 ischemic colitis 10.3 F2 SERPINC1 VEGFA
21 hemoglobin c disease 10.3 HBB MTHFR
22 eclampsia 10.3 F2 MTHFR SERPINC1
23 spinal cord infarction 10.3 F2 MTHFR SERPINC1
24 thalassemia 10.3 BCL11A HBB HBS1L
25 livedoid vasculitis 10.3 F2 MTHFR SERPINC1
26 thrombophlebitis 10.3 F2 MTHFR SERPINC1
27 sickle cell disease 10.3 BCL11A HBB HBS1L
28 antithrombin iii deficiency 10.3 F2 MTHFR SERPINC1
29 portal vein thrombosis 10.2 F2 MTHFR SERPINC1
30 placental abruption 10.2 F2 MTHFR SERPINC1
31 hemifacial spasm 10.2 MTHFR VEGFA
32 protein c deficiency 10.2 F2 MTHFR SERPINC1
33 ischemic optic neuropathy 10.2 F2 MTHFR SERPINC1
34 nonarteritic anterior ischemic optic neuropathy 10.2 F2 MTHFR SERPINC1
35 streptococcal toxic-shock syndrome 10.2 IL6 MYOM2
36 alpha thalassemia-intellectual disability syndrome type 1 10.2 BCL11A HBB MTHFR
37 homocysteinemia 10.2 F2 MTHFR SERPINC1
38 patent foramen ovale 10.2 F2 MTHFR SERPINC1
39 endocarditis 10.2 F2 IL6 SERPINC1
40 plasma protein metabolism disease 10.2 CD38 MAG MYOM2
41 ischemic neuropathy 10.2 F2 MTHFR
42 post-thrombotic syndrome 10.2 F2 IL6 SERPINC1
43 non-secretory myeloma 10.2 B2M CD38 MYOM2
44 osteosclerotic myeloma 10.2 IL6 MAG MYOM2
45 polyclonal hypergammaglobulinemia 10.2 IL6 MYOM2
46 toxic shock syndrome 10.2 IL6 MYOM2 SERPINC1
47 beta-thalassemia 10.2 BCL11A HBB HBS1L
48 extramedullary plasmacytoma 10.1 B2M IL6 MYOM2
49 papilledema 10.1 F2 MYOM2
50 critical limb ischemia 10.1 IL6 VEGFA

Graphical network of the top 20 diseases related to Blood Protein Disease:



Diseases related to Blood Protein Disease

Symptoms & Phenotypes for Blood Protein Disease

MGI Mouse Phenotypes related to Blood Protein Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 B2M BCL11A C4B CD38 F2 F3
2 homeostasis/metabolism MP:0005376 10.18 B2M BCL11A C4B CD38 F2 F3
3 cardiovascular system MP:0005385 10.09 B2M C4B F2 F3 IL6 NSD2
4 immune system MP:0005387 10.06 B2M BCL11A C4B CD38 F2 F3
5 mortality/aging MP:0010768 9.93 B2M BCL11A C4B F2 F3 IL6
6 liver/biliary system MP:0005370 9.8 B2M C4B IL6 MTHFR PROS1 SERPINC1
7 nervous system MP:0003631 9.7 B2M BCL11A F2 F3 IL6 MAG
8 vision/eye MP:0005391 9.17 F3 HBS1L IL6 MTHFR NCAM1 SERPINC1

Drugs & Therapeutics for Blood Protein Disease

Drugs for Blood Protein Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 750)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 460612 4053
2
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
4
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
9
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
10
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Phase 1 723-46-6 5329
11
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
12
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 738-70-5 5578
13
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
14
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
15
Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
16
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
17
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
18
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
19
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
20
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
21
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6, 15438-31-0 27284 23925
22
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
23
tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1401-55-4
24 Daratumumab Approved Phase 4,Phase 2,Phase 3,Phase 1 945721-28-8
25
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
26
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
27
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
28
Phentolamine Approved Phase 4 50-60-2 5775
29
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
30
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
31
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
32
Norepinephrine Approved Phase 4 51-41-2 439260
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Glucagon Approved Phase 4 16941-32-5
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
36
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
37
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 56-45-1 5951
38
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
39
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 31703
40
Pirarubicin Investigational Phase 4 72496-41-4
41 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2633)
# Name Status NCT ID Phase Drugs
1 Hypoalbuminemia in Burn Patients Unknown status NCT01436292 Phase 4 5% human albumin solution (HAS)
2 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
3 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
4 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
5 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
6 Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response Completed NCT00522821 Phase 4 intravenous immunoglobulins;antibiotics
7 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4 Vivaglobin
8 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
9 The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia Completed NCT01822600 Phase 4 Human albumin;Omeprazole
10 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
11 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
12 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
13 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
14 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
15 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
16 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
17 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
18 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
19 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
21 SUbstition of PERioperative Albumin Deficiency Disorders Recruiting NCT03167645 Phase 4 Human albumin
22 RDD Versus VDD Followed by ASCT in Newly Diagnosed Young Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
23 STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
24 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
25 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
26 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
27 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
28 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
29 Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients Recruiting NCT02755155 Phase 4 Human serum albumin infusion 4%;Human serum albumin infusion 20%
30 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
31 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
32 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Active, not recruiting NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
33 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
34 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
35 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
36 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
37 Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma Not yet recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
38 A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Not yet recruiting NCT03768960 Phase 4 Daratumumab
39 Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery Terminated NCT01547728 Phase 4 Recombinant antithrombin (rhAT)
40 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
41 Atenativ Effect on Uterine Blood Flow and Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
42 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
43 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
44 IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency Unknown status NCT01992328 Phase 3 Immune Globulin
45 Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Unknown status NCT01581593 Phase 3
46 Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity Unknown status NCT02708771 Phase 3 Polyunsaturated fatty acids omega-3;Placebo
47 CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
48 CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
49 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
50 Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs Unknown status NCT02066454 Phase 3 Apixaban

Search NIH Clinical Center for Blood Protein Disease

Cochrane evidence based reviews: blood protein disorders

Genetic Tests for Blood Protein Disease

Anatomical Context for Blood Protein Disease

MalaCards organs/tissues related to Blood Protein Disease:

42
Bone, T Cells, Bone Marrow, B Cells, Kidney, Testes, Myeloid

Publications for Blood Protein Disease

Variations for Blood Protein Disease

Expression for Blood Protein Disease

Search GEO for disease gene expression data for Blood Protein Disease.

Pathways for Blood Protein Disease

GO Terms for Blood Protein Disease

Cellular components related to Blood Protein Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 B2M C4A C4B CD38 F2 HBB
2 extracellular space GO:0005615 9.85 B2M C4A C4B F2 F3 HBB
3 cell surface GO:0009986 9.77 B2M CD38 F3 NCAM1 VEGFA
4 extracellular region GO:0005576 9.7 B2M C4A C4B F2 F3 HBB
5 endoplasmic reticulum lumen GO:0005788 9.65 B2M C4A F2 IL6 SERPINC1
6 blood microparticle GO:0072562 9.1 C4A C4B F2 HBB PROS1 SERPINC1

Biological processes related to Blood Protein Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of endopeptidase activity GO:0010951 9.62 C4A C4B PROS1 SERPINC1
2 negative regulation of neuron projection development GO:0010977 9.58 B2M CD38 MAG
3 regulation of complement activation GO:0030449 9.56 C4A C4B F2 PROS1
4 cellular protein metabolic process GO:0044267 9.55 B2M C4A F2 IL6 SERPINC1
5 cardiac muscle fiber development GO:0048739 9.51 MYOM2 VEGFA
6 negative regulation of bone resorption GO:0045779 9.49 CD38 IL6
7 regulation of blood coagulation GO:0030193 9.48 F2 SERPINC1
8 commissural neuron axon guidance GO:0071679 9.46 NCAM1 VEGFA
9 positive regulation of positive chemotaxis GO:0050927 9.43 F3 VEGFA
10 positive regulation of apoptotic cell clearance GO:2000427 9.37 C4A C4B
11 blood coagulation GO:0007596 9.35 F2 F3 HBB PROS1 SERPINC1
12 hemostasis GO:0007599 8.92 F2 F3 PROS1 SERPINC1

Molecular functions related to Blood Protein Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 8.96 F2 F3
2 endopeptidase inhibitor activity GO:0004866 8.8 C4A C4B PROS1

Sources for Blood Protein Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....